Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyHealthSpring LITT Policy Coverage Update | OpenPay…
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy SUR701.031

    Laser Interstitial Tumor Therapy (LITT)

    Customize your policy alerts

    Sign up for healthspring Policy SUR701.031 alerts

    Get alerted when Policy SUR701.031 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of magnetic resonance-guided laser interstitial tumor therapy for medically refractory epilepsy, brain tumors, and brain radiation necrosis, and identifies other uses as experimental, investigational, or unproven.

    Policy Summary
    PayerHealthSpring
    PolicyLaser Interstitial Tumor Therapy (LITT)
    Policy CodePolicy SUR701.031
    Change TypeNew medical policy
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionDocument that applicable medical necessity criteria and multidisciplinary review are satisfied before requesting authorization for MRI-guided intracranial LITT.
    SourceLink
    POLICY UPDATE CHANGES

    A new medical policy establishes that MRI-guided LITT for epilepsy, brain tumors, or brain radiation necrosis may be medically necessary when Coverage criteria are met, while all other indications are experimental, investigational, and/or unproven.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3Covered clinical categories
    2+Antiepileptic regimens required
    2Minimum physician specialists
    2FDA-cleared LITT systems discussed
    All otherOther indications considered unproven

    Medical Necessity and Unsupported Indications

    Medically Refractory Epilepsy

    Treatment of epilepsy using magnetic resonance image-guided laser interstitial tumor therapy (LITT) may be considered medically necessary when ALL of the following criteria are met:

    ALL of the following

    • There is documentation of disabling seizures despite use of 2 or more antiepileptic drug regimens (medically refractory epilepsy).
    • There are well-defined epileptogenic foci accessible by LITT.

    Brain Tumors or Brain Radiation Necrosis

    Treatment of brain tumors or radiation necrosis of the brain using MRI-guided LITT may be considered medically necessary when ALL of the following criteria are met:

    ALL of the following

    • LITT is being used to treat ONE of the following

      • Recurrent or progressive malignant tumor (primary or metastatic).
      • Lesion(s) inaccessible to surgical resection.
      • The individual is unable to tolerate surgical resection due to medical comorbidities.
    • The treatment plan to use LITT has been agreed upon by a multidisciplinary team of physicians to include at least 2 specialists (e.g., neurosurgery and oncology) and, after considering all relevant possible treatment approaches, is determined to be the best treatment option.

      LITT should be performed by a neurosurgeon who has completed procedure-specific training in the use of a Food and Drug Administration-approved LITT ablation system and who has been granted hospital privileges to perform brain tumor surgery and LITT ablation procedures.

    Covered Indications

    Coverage may be considered medically necessary when the applicable Coverage criteria are met.

    Treatment of epilepsy, brain tumors, or radiation necrosis of the brain using MRI-guided LITT meets the applicable medical-necessity criteria described in this section.

    Unproven or Unsupported Indications

    LITT is considered experimental, investigational, and/or unproven when ANY of the following applies:

    ANY of the following

    • The applicable medical-necessity criteria for treatment of epilepsy, brain tumors, or radiation necrosis of the brain are not met.
    • LITT is used for breast tumors, whether benign or malignant.
    • LITT is used for adrenal metastases.
    • LITT is used for liver metastases.
    • LITT is used for osteoid osteomas.

    Treatment of epilepsy using magnetic resonance image-guided LITT may be considered medically necessary when the medically refractory epilepsy criteria are met. Treatment of brain tumors or radiation necrosis of the brain using MRI-guided LITT may be considered medically necessary when the applicable criteria are met.

    LITT is considered experimental, investigational, and/or unproven when the applicable Coverage criteria are not met or for all other indications, including breast tumors, adrenal metastases, liver metastases, osteoid osteomas, lung cancer and lung metastasis, pancreatic cancer, spinal metastasis, prostate cancer, and thyroid nodules.

    As of January 1, 2022, CPT codes 61736 and 61737 are appropriate to report MRI-guided LITT, intracranial, for single and/or multiple or complex lesions. All other uses for LITT are typically billed as an unlisted code. Transperineal or transrectal focal laser ablation of the prostate with magnetic resonance-fused images or other enhanced ultrasound imaging is billed under CPT code 0655T.

    The NCCN Guidelines do not include MRI-guided LITT as a recommended treatment modality for breast cancer, adrenal metastasis, osteoid osteoma, spinal cancer, pancreatic cancer, or thyroid cancer.

    For non-small cell lung cancer, NCCN recommends thermal ablation techniques such as radiofrequency ablation, microwave ablation, and cryoablation in select individuals, but does not specifically include MRI-guided LITT among the listed thermal techniques.

    The NCCN guideline for small cell lung cancer does not specifically include MRI-guided LITT as a treatment option for small cell lung tumors.

    For liver cancer, including liver metastases, NCCN guidance discusses resection as the standard approach for local treatment of resectable metastatic disease. Ablative therapy, alone or in conjunction with resection, may be considered when all measurable disease can be treated; however, NCCN does not specifically address MRI-guided LITT as an ablation technique for colon or rectal cancer.

    For local prostate cancer, focal therapy is an experimental and emerging technology for initial treatment because randomized controlled trials with long-term follow-up have not demonstrated superiority or noninferiority to currently recommended management strategies; therefore, it is not a standard treatment. NCCN acknowledges that multiple focal laser ablative therapies are being investigated for localized and recurrent prostate cancer but does not specifically mention LITT.

    NCCN guidance discourages ablative focal therapy for individuals with high- or very-high-risk, regional, or metastatic prostate cancer outside a clinical trial. Active surveillance is preferred for low-risk prostate cancer, and focal therapies are discouraged in this population. For intermediate-risk prostate cancer, comparative-effectiveness evidence is insufficient and long-term efficacy and toxicity remain uncertain; focal therapy should therefore be used only in the context of a clinical trial.

    Billing and Coding Reference

    CPT codes for MRI-guided intracranial LITTCPT
    61736Magnetic resonance imaging-guided laser interstitial tumor therapy, intracranial, single lesion
    61737Magnetic resonance imaging-guided laser interstitial tumor therapy, intracranial, multiple or complex lesion(s)
    Prostate focal laser ablationCPTExperimental
    0655TTransperineal/transrectal focal laser ablation of the prostate with magnetic resonance fused images or other enhanced ultrasound imaging
    Other LITT usesCPT
    No codes listed
    FDA product codesmixed
    GEXFDA product code associated with LITT systems
    ONOFDA product code associated with LITT systems
    CPT CodesCPT
    19499
    20999
    27599
    32999
    47399
    48999
    53899
    55899
    60699
    61736
    1–10 of 13
    1/2
    HCPCS CodesHCPCS
    No codes listed
    Failed antiepileptic drug regimens
    Required treatment historyFailure of 2 or more antiepileptic drug regimens
    Clinical significanceIndicates medically refractory epilepsy when disabling seizures persist
    Documentation requirementDocument disabling seizures despite the medication regimens
    Multidisciplinary physician specialists
    Minimum team sizeAt least 2 physician specialists
    Example specialties

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Medical Necessity Review

    Before authorization, confirm and document that MRI-guided intracranial LITT meets the applicable medical-necessity criteria for epilepsy, brain tumor, or radiation necrosis. Coverage may be considered only when the relevant clinical indication and all required criteria are established.

    Documentation Required

    Epilepsy Clinical Documentation

    For epilepsy, submit documentation of disabling seizures despite treatment with two or more antiepileptic drug regimens, establishing medically refractory epilepsy, and well-defined epileptogenic foci that are accessible by LITT.

    • Document the seizure burden and disabling nature of the seizures.
    • Identify the failed antiepileptic drug regimens.
    • Provide diagnostic evidence of a well-defined, LITT-accessible epileptogenic focus.

    Procedure Overview

    Laser interstitial tumor therapy (LITT) is a minimally invasive procedure that places a laser fiber probe through a transcranial burr hole to thermally ablate targeted diseased tissue. Probe position, treatment time, and intensity are controlled under MRI guidance, while real-time MRI thermography monitors the thermal injury. Neurologic applications include treatment of epileptogenic foci, malignant brain tumors, and brain radiation necrosis, particularly when open surgery poses substantial morbidity or the lesion is surgically inaccessible.

    Key Terms

    Laser interstitial tumor therapy (LITT)
    ProcedureA minimally invasive thermal ablation procedure using a laser fiber probe to deliver thermal energy for targeted ablation of diseased tissue
    Cranial accessIn neurological applications, the probe is placed through a transcranial burr hole into the target brain tissue
    MRI controlProbe position, ablation time, and intensity are controlled under magnetic resonance imaging guidance, with thermal injury monitored by real-time MRI thermography
    LITT synonyms
    Laser-induced thermal therapyA synonym for laser interstitial tumor therapy
    Interstitial laser photocoagulationAlso called interstitial laser photocoagulation or coagulation
    Policy Summary
    PayerHealthSpring
    PolicyLaser Interstitial Tumor Therapy (LITT)
    Policy CodePolicy SUR701.031
    Change TypeNew medical policy
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionDocument that applicable medical necessity criteria and multidisciplinary review are satisfied before requesting authorization for MRI-guided intracranial LITT.
    SourceLink
    On This Page
    Medical Necessity and Unsupported IndicationsBilling and Coding ReferenceAuthorization, Documentation, and Denial RisksProcedure OverviewKey Terms
    LITT is used for lung cancer or lung metastasis.
  1. LITT is used for pancreatic cancer.
  2. LITT is used for spinal metastasis or spinal cancer.
  3. LITT is used for prostate cancer.
  4. LITT is used for thyroid nodules or thyroid cancer.
  5. LITT is used for any other indication not addressed by the applicable Coverage criteria.
  6. Neurosurgery and oncology
    Treatment-plan requirementThe multidisciplinary team must determine that LITT is the best treatment option after considering all relevant treatment approaches
    Documentation Required

    Tumor or Radiation Necrosis Documentation

    For brain tumor or radiation necrosis treatment, document the qualifying diagnosis and why LITT is appropriate. The indication must involve a recurrent or progressive malignant primary or metastatic tumor, a lesion inaccessible to surgical resection, or inability to tolerate resection because of medical comorbidities.

    • For radiation necrosis, document the relevant history of radiation therapy for a primary brain tumor or metastatic disease and the clinical rationale for considering LITT.
    • Include imaging, pathology, treatment history, or other records supporting recurrence, progression, radiation necrosis, inaccessibility, or surgical intolerance.

    Unsupported block type: documentation

    Prior Authorization

    Provider, Device, and MRI Eligibility

    Verify that the procedure will use an FDA-approved LITT ablation system and will be performed by a neurosurgeon with procedure-specific training and hospital privileges for brain tumor surgery and LITT ablation. Confirm that the MRI-guided setting and patient are eligible for the selected system.

    • FDA-cleared systems described in the policy include Visualase and NeuroBlate; use an FDA-approved system appropriate to the indication.
    • Confirm the neurosurgeon's LITT training and hospital privileges.
    • Confirm MRI compatibility and absence of medical conditions or implanted devices contraindicated for MRI.
    • Do not proceed when the physician determines that LITT or invasive brain surgery is unacceptable.
    Documentation Required

    Radiation Necrosis Consultation

    When LITT is being considered for radiation necrosis, obtain consultation with a neurosurgeon trained in LITT, consistent with NCCN case-by-case guidance.

    • Document the LITT-trained neurosurgical consultation in the treatment record.

    Unsupported block type: documentation

    Denial Risk

    Criteria Not Met or Other Indication

    Deny coverage as experimental, investigational, and/or unproven when the applicable Coverage criteria are not met or when LITT is requested for an indication outside the policy's covered categories.

    • Apply the written Coverage criteria rather than relying on the presence or absence of procedure, service, supply, or device codes.
    • Document the unmet criterion or unsupported indication.
    Denial Risk

    Epilepsy Eligibility Deficiencies

    For epilepsy requests, coverage criteria are deficient when the record does not establish disabling seizures despite two or more antiepileptic drug regimens or does not identify a well-defined epileptogenic focus accessible by LITT.

    • Missing documentation of disabling seizures is a deficiency.
    • Fewer than two failed antiepileptic drug regimens do not establish the stated medically refractory epilepsy criterion.
    • An unconfirmed, poorly defined, or inaccessible epileptogenic focus does not meet the criterion.
    Denial Risk

    Tumor or Radiation Necrosis Criteria Deficiencies

    For tumor or radiation necrosis requests, deny or pend for additional information when the record fails to establish a qualifying diagnosis, recurrence or progression when applicable, lesion inaccessibility, inability to tolerate resection, or a documented rationale for using LITT.

    • The indication must fit recurrent or progressive malignant tumor, an unresectable or inaccessible lesion, or medical inability to tolerate resection.
    • Radiation necrosis documentation should support the diagnosis, relevant radiation history, and case-specific rationale for LITT.
    • Absence of the required neurosurgical consultation for a radiation necrosis case is a documentation deficiency.
    Denial Risk

    Provider, Device, or MRI Eligibility Deficiencies

    Deny or pend the request when the device, provider, patient, or MRI setting is ineligible. The record must support use of an FDA-approved system by a properly trained and privileged neurosurgeon in an MRI-compatible setting.

    • A non-approved or inappropriate LITT system does not meet the policy requirement.
    • An untrained neurosurgeon or a surgeon without required hospital privileges is ineligible.
    • MRI contraindications involving the patient or implanted medical devices must be resolved before treatment.
    • The selected system's MRI-guidance and indication requirements must be satisfied.
    Denial Risk

    Unsupported Indication or Unmet Criteria

    Coverage is not supported when the Coverage criteria are unmet or when the requested use is outside the covered epilepsy, brain tumor, or brain radiation-necrosis categories. Such requests are considered experimental, investigational, and/or unproven under the policy.

    • Identify each unmet medical-necessity or documentation requirement.
    • Do not infer coverage from coding references or from investigational applications described in the policy.
    Denial Risk

    Prostate Focal Laser Ablation

    Transperineal focal laser ablation for localized prostate cancer is an experimental and emerging application, not a standard covered LITT indication under this policy. It should be used only in the context of a clinical trial.

    • Do not approve outside a clinical trial based on the policy's discussion of insufficient comparative-effectiveness evidence and uncertain long-term efficacy and toxicity.
    • Focal therapy is discouraged outside a clinical trial for high- or very-high-risk, regional, or metastatic disease and is not preferred for low-risk disease.
    Additional termsThermotherapy, interstitial laser therapy (ILT), MRI-guided LITT, and stereotactic laser ablation
    Drug-resistant or medically refractory epilepsy
    DefinitionEpilepsy in which seizures persist and seizure freedom is very unlikely with further antiseizure medication treatment
    Medication thresholdFailure of adequate trials of 2 tolerated, appropriately chosen, and appropriately used antiseizure medication schedules
    Treatment approachThe medication schedules may be used as monotherapy or in combination
    MRI-guided LITT
    DefinitionMagnetic resonance image-guided laser interstitial tumor therapy
    Imaging guidanceUses magnetic resonance imaging to guide the LITT procedure
    Clinical applicationThe policy addresses MRI-guided LITT for epilepsy, brain tumors, and brain radiation necrosis when applicable coverage criteria are met
    Focal laser ablation for localized prostate cancer
    Treatment targetAblative treatment directed at a focal prostate lesion rather than the entire prostate
    Clinical useDescribed as an experimental and emerging technology for the initial treatment of localized prostate cancer
    Evidence statusIt is not a standard treatment because randomized controlled trials with long-term follow-up have not established superiority or noninferiority to current recommended management strategies